Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions
Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions
复制标题
非小细胞肺癌中的免疫检查点抑制剂：现状和未来方向
DOI：
10.1093/bfgp/ely029
复制
发表时间：
2019
影响因子：
4
通讯作者：
Wu Yao gui
中科院分区：
文献类型：
--
作者：
Yan Ya fei;Zheng Yong fa;Ming Ping po;Deng Xiao xi;Ge Wei;Wu Yao gui
自2015年以来，免疫治疗，特别是免疫检查点抑制剂（ICI）在非小细胞肺癌（NSCLC）中取得了重大突破。其中，nivolumab、pembrolizumab和atezolizumab已获得美国食品药品监督管理局批准用于NSCLC。联合收割机将ICIs与化疗、放疗、抗血管治疗和靶向治疗相结合势在必行。但在光明的未来，有两个问题。一个是如何使用生物标志物来选择受益人。另一个是如何在药物有效性和安全性之间取得平衡。目前已有7种靶向程序性死亡-1/程序性死亡配体-1（PD-1/PD-L1）和细胞毒性T淋巴细胞相关抗原-4（CTLA-4）通路的药物已经或有望进入临床治疗。本综述重点关注这些药物，并总结了已报告或正在进行的临床试验已经进入招募状态。
Since 2015, immunotherapies, especially immune checkpoint inhibitors (ICIs), have made great breakthroughs in non-small-cell lung cancer (NSCLC). Among them, nivolumab, pembrolizumab and atezolizumab have been granted US Food and Drug Administration approval for NSCLC. It is imperative to combine ICIs with chemotherapy, radiotherapy, antivascular therapy and targeted therapy. But in the bright future, there are two problems. One is how to use biomarkers to select the beneficiaries. The other is how to achieve a balance between drug effectiveness and safety. There are now seven drugs targeting the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathways that have been or are expected to enter clinical treatment. This review focuses on these drugs and summarizes clinical trials that have been reported or that ongoing ones have already entered the recruiting state.